Loading...
XSHG
603963
Market cap35mUSD
Feb 10, Last price  
1.18CNY
Name

Dali Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
2.97
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.81%
Rev. gr., 5y
-26.30%
Revenues
87m
-34.06%
285,267,963297,649,847338,686,426266,965,263275,764,813272,739,025401,483,012294,324,901213,583,457171,493,284132,344,03387,269,974
Net income
-20m
94,594,08892,031,892100,069,95662,292,68162,165,67544,452,48510,700,46513,505,4923,231,66600-20,031,372
CFO
-26m
100,745,768106,593,76895,854,270114,864,82988,682,70626,916,67178,115,4667,328,803010,509,2750-26,006,525
Dividend
Jun 23, 20210.046 CNY/sh
Earnings
May 16, 2025

Profile

Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.
URL
http://www.daliyaoye.cn/
IPO date
Sep 22, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
87,270
-34.06%
132,344
-22.83%
Cost of revenue
96,821
137,449
Unusual Expense (Income)
NOPBT
(9,551)
(5,105)
NOPBT Margin
Operating Taxes
2,663
704
Tax Rate
NOPAT
(12,214)
(5,809)
Net income
(20,031)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
8,010
21,399
Long-term debt
15,681
27,157
Deferred revenue
346
434
Other long-term liabilities
1
Net debt
(197,304)
(288,184)
Cash flow
Cash from operating activities
(26,007)
CAPEX
(7,699)
Cash from investing activities
20,362
Cash from financing activities
(24,000)
FCF
(10,769)
46,385
Balance
Cash
220,932
273,072
Long term investments
63
63,668
Excess cash
216,632
330,123
Stockholders' equity
230,657
283,357
Invested Capital
187,699
157,796
ROIC
ROCE
EV
Common stock shares outstanding
222,571
219,700
Price
11.88
-9.04%
13.06
47.74%
Market cap
2,644,141
-7.85%
2,869,282
47.74%
EV
2,446,837
2,581,098
EBITDA
6,454
12,744
EV/EBITDA
379.13
202.53
Interest
1,724
1,078
Interest/NOPBT